{"classes":[{"categories":[{"measurements":[{"comment":"NA indicates that upper limit of confidence interval (CI) was not estimable due to insufficient number of participants with events at study closure.","groupId":"OG000","lowerLimit":"7.2","upperLimit":"NA","value":"11.3"},{"comment":"NA indicates that upper limit of CI was not estimable due to insufficient number of participants with events at study closure.","groupId":"OG001","lowerLimit":"5.6","upperLimit":"NA","value":"13.0"},{"groupId":"OG002","lowerLimit":"3.7","upperLimit":"12.8","value":"5.8"},{"comment":"NA indicates that upper limit of CI was not estimable due to insufficient number of participants with events at study closure.","groupId":"OG003","lowerLimit":"2.1","upperLimit":"NA","value":"5.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"163"},{"groupId":"OG003","value":"71"}],"units":"Participants"}],"description":"The time (in months) from the date of the initial response (CR or PR, whichever was first) until the date of the first documented disease progression per an Independent Review Committee (for Groups 1 and 2), per Investigator (Group 3), or death due to any cause. Patients who were alive and progression free at the time of the analysis were censored at the last date where the patient was known to be in response. Note: the DOR was censored, meaning data collection was stopped early for analysis, making the top limit of the 95% confidence interval not estimable (NE). Per RECIST v.1.0, CR was defined as disappearance of all target and non-target lesions and any pathological lymph nodes must be \\<10 mm in the short axis. The PR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with R/R FL with mutant EZH2 treated with tazemetostat as a single agent in Phase 2 of the study. Patients received 800 mg of tazemetostat, orally BID, administered in continuous 28-day treatment cycles until confirmed disease progression, unacceptable toxicity, or withdrawal of consent.","id":"OG000","title":"Phase 2 Group 1: Tazemetostat in R/R FL With Mutant EZH2"},{"description":"Patients with R/R FL with wild-type EZH2 treated with tazemetostat as a single agent in Phase 2 of the study. Patients received 800 mg of tazemetostat, orally BID, administered in continuous 28-day treatment cycles until confirmed disease progression, unacceptable toxicity, or withdrawal of consent.","id":"OG001","title":"Phase 2 Group 2: Tazemetostat in R/R FL With Wild-Type EZH2"},{"description":"Patients with R/R DLBCL received 800 mg of tazemetostat monotherapy, orally BID, administered in continuous 28-day treatment cycles until confirmed disease progression, unacceptable toxicity, or withdrawal of consent.","id":"OG002","title":"Phase 2 Group 3: Tazemetostat in R/R DLBCL Monotherapy"},{"description":"Patients received tazemetostat 800 mg tablets orally BID in continuous 28-day treatment cycles until confirmed disease progression, unacceptable toxicity, or withdrawal of consent. In addition, these patients also received prednisolone 40 mg/m\\^2 on Days 1 to 5 and 15 to 19 from Cycle 1 to Cycle 4 post which tazemetostat monotherapy was continued.","id":"OG003","title":"Phase 2 Group 4: Tazemetostat + Prednisone in R/R DLBCL Combination Therapy"}],"paramType":"MEDIAN","populationDescription":"Patients who had a complete or partial response per an Independent Review Committee. Note: the DOR for some patients was censored, meaning data collection was stopped early for analysis making the top limit of the 95% confidence interval not estimable.","reportingStatus":"POSTED","timeFrame":"Radiologic tumor assessments performed at baseline (within 28 days before start of study treatment) and every 8 weeks during Cycles 2 to 6, and then every 12 weeks thereafter until confirmed PD/death, a maximum of approximately 82 months","title":"Duration of Response for Tazemetostat as a Single Agent or in Combination With Prednisolone (Phase 2 Only)","type":"SECONDARY","unitOfMeasure":"months"}